← The record

Dabrafenib And Trametinib

Recommended OncologyAuthority Required 💬 consumer voice

Treatment of adult patients with advanced (metastatic) Stage IV non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

4
Submissions
2 resub
2015–25
On the record
$15k–45k
ICER range
1 sourced ICER · 2019
Cost-min
Cost basis

Decisions on record

2 decisions
  • Meeting Mar 2025 Recommended Non-small cell lung cancer (NSCLC) with BRAF V600E mutation, advanced or metastatic
  • Meeting Mar 2024 Recommended Paediatric glioma (BRAF V600E mutation positive low grade and high grade)

Access path

4 submissions · public record
  1. Nov 2015
    Recommended · restricted
  2. Jul 2019
    Recommended · restricted

    Listing: Restricted → Authority Required

  3. Dec 2024
    Recommended · restricted

    Comparator changed: placebo → LGG: carboplatin and vincristine (C+V); HGG: basket of…

  4. Mar 2025
    Recommended · restricted

    Comparator changed: LGG: carboplatin and vincristine (C+V); HGG: basket of chemotherapy…

  5. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
The PBAC recommended an Authority Required (STREAMLINED) listing of dabrafenib in combination with trametinib (D+T) for the treatment of adult patients with BRAF V600E mutation positive metastatic (Stage IV) non-small cell lung cancer (NSCLC).PSD · Mar 2025
The PBAC noted the small population of patients with BRAF V600E mutations and the moderate clinical need for additional therapies for NSCLC, which was supported by the consumer comments received.PSD · Mar 2025
Economic analysis
The submission presented a cost-minimisation approach (CMA) comparing D+T with pembrolizumab+PBC based on the claim of non-inferiority in terms of effectiveness and safety.PSD · Mar 2025
The submission presented two separate CMAs for NSQ and SQ NSCLC, given the differences in the components of PBC and treatment duration of pembrolizumab+PBC based on histology. The comparator therapies considered in the CMA were pembrolizumab with cisplatin/carboplatin and pemetrexed for NSQ NSCLC and pembrolizumab with carboplatin and paclitaxel for SQ NSCLC.PSD · Mar 2025
Clinical claim
D+T has non-inferior efficacy versus pembrolizumab + platinum-based chemotherapy based on ORR, PFS and OS D+T has different but non-inferior safety to pembrolizumab + platinum-based chemotherapy For ECOG PS 2:PSD · Mar 2025
D+T has superior efficacy and safety to platinum-based chemotherapy Source: Table 1.1, p3 of the submission.PSD · Mar 2025
Consumer comments
The PBAC noted and welcomed the input from individuals (3), a health care professional and organisations (3) via the Consumer Comments facility on the PBS website. The comments from the health care professional noted the good overall response rate observed with D+T. Comments from individuals noted the high burden of NSCLC on patients and their families and the high cost of D+T.PSD · Mar 2025
The PBAC noted the Lung Foundation Australia and Rare Cancers Australia commented on the importance of having access to targeted therapies for NSCLC. The 5PSD · Mar 2025

Cost-effectiveness

1 sourced ICER · 2019

Cost-minimisation approach used; no ICER calculated by design.

The submission presented a cost-minimisation approach (CMA) comparing D+T with pembrolizumab+PBC based on the claim of non-inferiority in terms of effectiveness and safety. PSD · 2025

Decision context

PopulationAdult patients with advanced (metastatic) Stage IV BRAF V600E mutation-positive non-small cell lung cancer with ECOG performance status 0-2.

Submission history

4 entries
DecidedOutcomeComparatorICEREvidence
Mar 2025 Recommended · restricted Pembrolizumab with platinum-based chemotherapy (ECOG PS 0-1); platinum-based chemotherapy alone (ECOG PS 2) Single-arm · ORR
Dec 2024 Recommended · restricted LGG: carboplatin and vincristine (C+V); HGG: basket of chemotherapy treatments (carboplatin, vincristine, etoposide, tem RCT · ORR
Jul 2019 Recommended · restricted placebo $15k–45k RCT · RFS
Nov 2015 Recommended · restricted

Clinical evidence

Trials cited in the PSDs · ClinicalTrials.gov
TrialPhaseNPrimary outcomeStatus
COMBI-AD Ph 3 870 Percentage of Participants With Relapse-free Survival (RFS) Events completed
COMBI-V Ph 3 704 Overall Survival (OS) completed

Consumer voice

Mar 2025

Consumer input from individuals, health care professionals, and organisations noted the high burden of NSCLC on patients and families, the high cost of treatment, and strong support for access to targeted therapies including oral treatment options.

Comments from individuals noted the high burden of NSCLC on patients and their families and the high cost of D+T. Consumer comments · PSD
treatment burdenunmet needout-of-pocket costaccess barriersquality of life

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to BRAF V600E mutation specifically and requires ECOG performance status 0-2; TGA label covers broader V600 mutations without performance status restriction.